RE: with all22 Jul 2020 08:32
Sally87 .. this will rise on BAMS news, then rise again when saliva test confirms efficacy.
You would expect from here to reach £2 per share BEFORE saliva test, and double or triple on saliva test release (or more)
But .. the key here is NOT that we can have a BAMS test, or a successful Saliva test, but that we have the unique ability now to tackle ANY future virus, (and apply technology to existing viruses).
You need to forget Covid for a moment, and analyse the company up to January 2020, and understand the game changing abilities that the company was all about, in the delivery of chemotherapy drugs that is completely disruptive to ALL existing delivery mechanisms of chemotherapy, and understand that it is not just the delivery method, but the fact that Avacta has uncovered the whole grail in that the cancer treatments will allow existing drugs that have excellent properties for reducing cancer that currently are limited in potency due to the serious side effects from being used in high enough doses, to allowing these drugs to be used at very high doses, virtually eliminating the side effects, and therefore being a total game changer to Oncology around the world.
Then you have the fact that the company just raised over £40,million at £1,20 of which a mahpjor portion is allocated to oncology, plus the fact that COVID now looks likely to dwarf the fund raising in the level of cash the company will have once launching the saliva test, and opening the door to EVERY hospital around the world that do not have the modern technologies or money to be making sophisticated tests due to lack of equipment to have a gold standard test running on existing equipment found in any hospital anywhere.
So to ask what will this rise to, the answer is it won’t stop rising for a very long time, and it simply becomes a case of take your money when you need it, and if you don’t, then leave it to grow here.
Sign In
Follow the stocks
